Biocytogen (HKEX: 02315) is excited to announce our attendance at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston, TX, from November 6-10, 2024!

Additionally, we invite you to stop by booth #319 to meet our team and learn how our antibody assets, fully human antibody discovery platform, animal/cell models, and pharmacology services can help accelerate your drug development process.

Exhibition Sessions:

• Booth Number: #319
• Date: November 8-10, 2024 (Friday-Sunday)
• Location: George R. Brown Convention Center, Houston, TX

Poster Sessions:

• Date: November 7-9, 2024 (Thursday-Saturday)
• Location: Exhibit Halls A & B, George R. Brown Convention Center

BioMice - Preclinical Models and Services Division

• Preclinical pharmacology services, including in vivo efficacy evaluation, in vivo pharmacology analysis, PK/PD analysis, diagnosis/pathology/toxicology evaluations
• 3300+ World-class novel animal and cell models
• Gene editing mouse/cell line services

Poster Presentations:

Friday, Nov. 8:

• #3: Humanized HER2-expressing tumor cells established syngeneic models for evaluating HER2 antibody-drug conjugate (ADC) therapy
• #7: The pairing of CD200 humanized cancer cells with CD200 and CD200R double humanized mice for the preclinical evaluation of the combination of anti-human CD200 antibodies and immune checkpoint drugs

Saturday, Nov. 9:

• #4: Establishing a tumor cell model to evaluate the bystander effect of antibody-drug conjugate (ADC) therapies
• #6: A novel IL12Rβ1 and IL12Rβ2 humanized mouse model for preclinical efficacy and toxicity evaluation of human IL-12 analogs

RenBiologics - Innovative Antibody Drug Discovery Division

• Powered by Biocytogen’s proprietary RenMiceTM fully human antibody discovery platform
• Enables the development of monoclonal antibodies, bispecific antibodies, bispecific ADCs, nanobodies, and TCR-like antibodies
• Offers various commercial models, including antibody licensing, transfer, and co-development partnerships
• Features a shelf library of over 400,000 fully human antibody sequences targeting around 1,000 antigens, with approximately 150 partnerships already established

Poster Presentations:

Thursday, Nov. 7 & Friday, Nov. 8:

• #1049: TAA antibody library and novel linker/payload BLD1102 for ADC, bispecific ADC and nanobody-drug conjugate development

We look forward to exploring collaboration opportunities that can support your R&D needs.

To learn more, please click here to contact us.